L

    Lantern Pharma Inc (LTRN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.71
    +0.00 (+0.00%)

    Market Cap: $21.86M

    Last updated: Sep 15, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    80%(20/25)
    Avg Surprise
    +12.09%
    Streak
    6 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.38
    Range$-0.38 - $-0.38
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$0.00+100.0%
    30d ago$-0.38+0.0%
    7d ago$-0.38+0.0%
    Current$-0.38
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.39
    Range$-0.39 - $-0.39
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.39---
    Sep 26EST
    		-$-0.38---
    Jun 26
    Reported Aug 14
    		$-0.28$-0.38+26.32%Beat+30.0%
    Mar 26
    Reported May 15
    		$-0.30$-0.36+16.67%Beat+28.6%
    Dec 25
    Reported Mar 30
    		$-0.36$-0.46+21.74%Beat+33.3%
    Sep 25
    Reported Nov 12
    		$-0.39$-0.47+17.02%Beat+7.1%
    Jun 25
    Reported Aug 13
    		$-0.40$-0.48+16.67%Beat+13.0%
    Mar 25
    Reported May 15
    		$-0.42$-0.43+2.33%Beat+17.6%
    Dec 24
    Reported Mar 27
    		$-0.54$-0.51-5.88%Miss-38.5%
    Sep 24
    Reported Nov 7
    		$-0.42$-0.56+25.00%Beat-44.8%
    Jun 24
    Reported Aug 8
    		$-0.46$-0.55+16.36%Beat-4.5%
    Mar 24
    Reported May 9
    		$-0.51$-0.43-18.60%Miss-41.7%
    Dec 23
    Reported Mar 18
    		$-0.39$-0.40+2.50%Beat-25.8%
    Sep 23
    Reported Nov 8
    		$-0.29$-0.48+39.58%Beat-38.1%
    Jun 23
    Reported Aug 9
    		$-0.44$-0.45+2.22%Beat-7.3%
    Mar 23
    Reported May 9
    		$-0.36$-0.48+25.00%Beat+5.3%
    Dec 22
    Reported Mar 20
    		$-0.31$-0.47+34.04%Beat+3.1%
    Sep 22
    Reported Nov 7
    		$-0.21N/A+56.25%Beat+41.7%
    Jun 22
    Reported Aug 8
    		$-0.41$-0.52+21.15%Beat-95.2%
    Mar 22
    Reported May 3
    		$-0.38$-0.29-31.03%Miss-58.3%
    Dec 21
    Reported Mar 10
    		$-0.32$-0.40+20.00%Beat+31.9%
    Sep 21
    Reported Nov 1
    		$-0.36$-0.24-50.00%Miss-33.3%
    Jun 21
    Reported Jul 29
    		$-0.21$-0.26+19.23%Beat+32.3%
    Mar 21
    Reported May 3
    		$-0.24$-0.27+11.11%Beat+40.0%
    Dec 20
    Reported Mar 10
    		$-0.47$-0.45-4.44%Miss-
    Sep 20
    Reported Oct 29
    		$-0.27$-0.35+22.86%Beat-
    Jun 20
    Reported Jul 30
    		$-0.31$-0.37+16.22%Beat-
    Mar 20
    Reported Jun 12
    		$-0.40$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-1.29EV/EBITDA0.21x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-400.90%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio1.96xQuick Ratio1.96x
    Trading Statistics
    Beta2.30Avg Volume152.73K
    52-Week High$4.7052-Week Low$1.11

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.85
    SMA 20$2.07
    SMA 50$2.59
    SMA 200$2.89
    EMA 10$1.86
    EMA 20$2.06
    EMA 50$2.46
    EMA 200$2.93

    MACD

    Line: -0.26Signal: -0.25Hist: -0.01

    ADX

    ADX: 37.5+DI: 9.5-DI: 23.0

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down96.0
    PSAR$1.95

    Bollinger Bands

    Upper Band$2.62
    Lower Band$1.53
    %B Position5242%(Upper)
    Band Width0.17

    RSI (14-Day)

    Oversold
    20.7

    Momentum Oscillators

    Stoch %K2.9
    Stoch %D3.0
    Williams %R-98.4
    ROC (10d)-17.4%
    Momentum-0.36
    CCI (20d)-109.0
    MFI (14d)41.0

    Volatility Measures

    ATR (14d)$0.18(10.4%)
    StdDev (20d)0.27
    Hist Vol50.4%(High)

    Volume Flow

    VWAP$1.74
    OBV21.3M
    AD Line-23.4M
    CMF (20d)-0.442

    Volume Metrics

    Avg Vol (20d)152.7K
    Vol Ratio0.7x
    VWMA (20d)$2.06

    Pivot Points

    R3$1.91
    R2$1.86
    R1$1.79
    Pivot Point$1.74
    S1$1.67
    S2$1.62
    S3$1.55

    Advanced Oscillators

    TSI-51.10
    Ultimate Osc25.4
    KST-298.78

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$100,654$0$0$0$261,052$0
    Cost of Revenue$0$0$-4,102$0$0$0$51,224$0$0$0$44,317$0
    Gross Profit$0$0$4,102$0$0$0$-51,224$0$0$0$-44,317$0
    Operating Expenses$3.51M$3.41M$4.20M$4.35M$4.65M$4.77M$5.90M$5.18M$5.41M$5.73M$4.88M$3.52M
    R&D$1.79M$1.72M$2.74M$2.44M$3.07M$3.26M$4.27M$3.72M$3.89M$4.25M$3.57M$2.21M
    SG&A$1.72M$1.68M$1.46M$1.91M$1.58M$1.51M$1.63M$1.46M$1.52M$1.48M$1.30M$1.31M
    Operating Income$-3,508,090$-3,405,247$-4,202,762$-4,349,800$-4,651,900$-4,774,032$-5,896,399$-5,179,576$-5,408,461$-5,732,001$-4,877,384$-3,523,621
    Interest Income$30,079$42,160$72,475$100,921$114,745$149,790$161,393$191,352$188,660$200,950$267,389$246,394
    Interest Expense$3.58M$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-7,087,050$-3,329,171$-4,074,217$-4,177,423$-4,331,015$-4,536,783$-5,875,200$-4,505,697$-4,959,506$-5,440,810$-4,185,921$-3,161,450
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-7,072,124$-3,329,171$-4,074,217$-4,177,423$-4,331,015$-4,536,783$-5,875,200$-4,505,697$-4,959,506$-5,440,810$-4,185,921$-3,161,450
    EBITDA$-7,113,378$-3,367,478$-4,168,076$-4,274,242$-4,502,811$-4,753,372$-6,090,920$-4,692,660$-5,143,908$-5,671,768$-4,507,026$-3,432,950
    EBIT$-7,117,129$-3,371,331$-4,146,692$-4,278,344$-4,445,760$-4,686,573$-6,036,593$-4,697,049$-5,148,166$-5,641,760$-4,453,310$-3,407,844
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about LTRN

    News

    New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST)

    New to The Street announced a broadcast featuring executive interviews with Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC), and FreeCast (NASDAQ:CAST) airing at 6:30 PM ET across Bloomberg Television in the U.S., Latin America, and MENA. The program highlights each company's strategies and market opportunities in biotechnology, AI, public safety, and streaming technology. Additionally, New to The Street will expand its international distribution to Southeast Asia starting October 3, 2026, reaching approximately 68 million additional households.

    Yahoo! Finance Canada•9/5/26•
    Bullish

    New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST)

    New to The Street will broadcast interviews with Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC), and FreeCast (NASDAQ:CAST) at 6:30 PM ET across Bloomberg U.S., Latin America, and MENA. The program will highlight these companies' advancements in AI-driven oncology, public safety technology, and streaming services. Additionally, New to The Street announced an expansion into Southeast Asia starting October 3, 2026, reaching an additional 68 million households.

    Yahoo Finance•9/5/26•
    Bullish

    Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript

    Lantern Pharma (LTRN) discussed its Q2 2026 earnings, highlighting a 25% reduction in operating expenses year-over-year while advancing multiple clinical programs. A significant development was the establishment of Open Medicine AI (OMAI) as a separate company to commercialize its AI platform, with Lantern Pharma retaining full ownership and access. The call also detailed promising clinical data for LP-300 in non-small cell lung cancer and LP-184 in bladder and triple-negative breast cancer, along with strategic financial priorities including securing additional funding.

    The Globe and Mail•8/22/26•
    Somewhat-Bullish

    Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript

    Lantern Pharma (LTRN) discussed its Q2 2026 earnings, highlighting a 25% reduction in operating expenses year-over-year while advancing multiple clinical programs. A significant development is the establishment of Open Medicine AI (OMAI) as a separate company to commercialize its AI platform, with Lantern Pharma retaining full ownership and access. The company also reported promising clinical data for LP-300 in non-small cell lung cancer and LP-184 in bladder cancer and triple-negative breast cancer, along with progress in its pediatric oncology programs.

    The Globe and Mail•8/21/26•
    Bullish

    Here's Why We're A Bit Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

    Lantern Pharma (NASDAQ:LTRN) faces concerns regarding its cash burn rate, with a cash runway of only about six months based on its US$14 million annual burn and US$7.4 million cash reserves as of June 2026. While the company has reduced its cash burn by 21% over the past year, its ability to raise additional capital is questionable given that its burn represents 48% of its US$30 million market capitalization, suggesting potential for a highly dilutive capital raise. This short runway and significant relative cash burn indicate a risky financial situation for the early-stage business.

    Sahm•8/21/26•
    Bearish

    Frequently Asked Questions About LTRN

    Does LTRN pay dividends?
    Lantern Pharma Inc (LTRN) does not currently pay a regular dividend.
    What is LTRN's market cap?
    Lantern Pharma Inc (LTRN) has a market capitalization of $21.86M with a current stock price of $1.71.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In